A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT ID: NCT03430843
Last Updated: 2024-10-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
512 participants
INTERVENTIONAL
2018-01-26
2022-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT03783442
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
NCT03957590
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT04732494
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
NCT07046221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tislelizumab
Tislelizumab on Day 1, given every 21 days
Tislelizumab
200 mg administered intravenously (IV)
Investigator chosen chemotherapy (ICC)
Paclitaxel on Day 1, given every 21 days or on a weekly schedule; OR Docetaxel on Day 1, given every 21 days; OR Irinotecan on Days 1 and 8, given every 21 days
Paclitaxel
135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
Docetaxel
75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
Irinotecan
125 mg/m\^2 administered IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tislelizumab
200 mg administered intravenously (IV)
Paclitaxel
135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
Docetaxel
75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
Irinotecan
125 mg/m\^2 administered IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Tumor progression during or after first-line treatment for advanced unresectable / metastatic ESCC
3. At least one measurable/evaluable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to randomization
Exclusion Criteria
2. History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within 6 months prior to randomization
3. Tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula in the study treatment assessed by investigator
4. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage
5. Received prior therapies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1)
6. Prior malignancy active within the previous 2 years (exceptions include the tumor under investigation in this trial, and locally recurring cancers that have undergone curative treatment, such as resected basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast)
7. Active brain or leptomeningeal metastasis.
8. Has active autoimmune disease or history of autoimmune diseases at high risk for relapse
9. Known history of, or any evidence of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases, etc
10. Known history of Human Immunodeficiency Virus (HIV)
11. Has cardiovascular risk factors
12. Pregnant or breastfeeding woman.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BeiGene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Hospital
Detroit, Michigan, United States
Toledo Clinic Cancer Center
Toledo, Ohio, United States
Imelda Ziekenhuis Bonheiden
Bonheiden, , Belgium
Cliniques Universitaires Saint Luc
Brussels, , Belgium
Uz Antwerpen
Edegem, , Belgium
University Hospitals Leuven
Leuven, , Belgium
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
The First Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, China
Huaian Second Peoples Hospital
Huaian, Jiangsu, China
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Nantong Tumor Hospital Branch South
Nantong, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Jiangxi Province Cancer Hospital
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
The Second Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
Shandong Cancer Hospital
Jinan, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
Weifang Peoples Hospital
Weifang, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanxi Provincial Peoples Hospital
Taiyuan, Shanxi, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, Sichuan, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Chru de Brest Hospital Morvan
Brest, , France
Centre Georges Francois Leclerc
Dijon, , France
Chu Besancon Hopital Jean Minjoz
Doubs, , France
Centre Oscar Lambret
Lille, , France
Hopital Prive Jean Mermoz
Lyon, , France
Icm Val Daurelle
Montpellier, , France
Chu Bordeaux Hopital Haut Leveque
Pessac, , France
Chu de Poitiers Site de La Mileterie
Poitiers, , France
Ico Site Rene Gauducheau
SaintHerblain, , France
Institut Gustave Roussy
Villejuif, , France
Charite Universitatsmedizin Berlin
Berlin, , Germany
Universitares Krebszentrum Leipzig
Leipzig, , Germany
Klinikum Johannes Gutenberg Universitaet Mainz
Mainz, , Germany
Ospedale Di Faenza
Faenza, , Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
Meldola, , Italy
Azienda Ospedaliero Universitaria San Luigi Gonzaga
Orbassano, , Italy
Aou Pisana, Stabilimento Di Santa Chiara
Pisa, , Italy
Ao Citta Della Salute E Della Scienza Di Torino Presidio O
Torino, , Italy
Akita University Hospital
Akitashi, Akita, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Nho Shikoku Cancer Center
Matsuyama, Ehime, Japan
Nho Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
St Marianna University School of Medicine Hospital
Yokohama, Kanagawa, Japan
Osaka International Cancer Institute
Osakashi, Osaka, Japan
Kindai University Hospital
Sayama, Osaka, Japan
Osaka University Hospital
Suitashi, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsukishi, Osaka, Japan
Saitama Cancer Center
Kitaadachigun, Saitama, Japan
Shizuoka Cancer Center
Suntogun, Shizuoka, Japan
National Cancer Center Hospital
Chuoku, Tokyo, Japan
Cancer Institute Hospital of Jfcr
Kotoku, Tokyo, Japan
Hiroshima University Hospital
Hiroshima, , Japan
Kochi Health Sciences Center
Kochi, , Japan
Kyoto University Hospital
Kyoto, , Japan
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Gachon University Gil Medical Center
Incheon, Incheon Gwang'yeogsi, South Korea
Chonnam National University Hwasun Hospital
HwasunGun, Jeollanam-do, South Korea
Asan Medical Center
Seoul, Seoul Teugbyeolsi, South Korea
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, South Korea
Korea University Guro Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Hospital Del Mar
Barcelona, , Spain
Hospital Universitario Vall Dhebron
Barcelona, , Spain
Institut Catala Doncologia
Barcelona, , Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Universitario Ramon Y Cajal
Madrid, , Spain
Hospital Universitario de Octubre
Madrid, , Spain
Hospital Universitario Hm Madrid Sanchinarro
Madrid, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Chi Mei Hospital Liouying
Tainan City, , Taiwan
National Taiwan University Hospital East Campus
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
The Christie Hospital
Greater Manchester, , United Kingdom
Guys and St Thomas Hospital Nhs Foundation Trust
London, , United Kingdom
Sarah Cannon Research Institute Uk
London, , United Kingdom
St Marys Hospital Imperial College Healthcare Nhs Trust
London, , United Kingdom
Mount Vernon Hospital (Mount Vernon Cancer Center)
Northwood, , United Kingdom
Royal Marsden Nhs Foundation Royal Marsden Hospital
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20.
Lu Z, Du W, Jiao X, Wang Y, Shi J, Shi Y, Shu Y, Niu Z, Hara H, Wu J, Hsu CH, Van Cutsem E, Brock MV, Zhang Z, Ding N, Zhang Y, Shen Z, Shen L. NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial. J Clin Oncol. 2025 Jun;43(16):1898-1909. doi: 10.1200/JCO-24-01818. Epub 2025 Apr 3.
He Q, Shi X, Yan J, Wu M, Gu C, Yu X. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second-line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study. Mol Clin Oncol. 2024 Feb 9;20(4):29. doi: 10.3892/mco.2024.2727. eCollection 2024 Apr.
Hara H, Satoh T, Kojima T, Tsushima T, Sunakawa Y, Okada M, Ding N, Wu H, Li L, Yu T, Barnes G, Kato K. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus. 2024 Apr;21(2):102-110. doi: 10.1007/s10388-023-01040-w. Epub 2024 Jan 19.
Kim SB, Van Cutsem E, Ajani J, Shen L, Barnes G, Ding N, Tao A, Xia T, Zhan L, Kato K. Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients. Curr Med Res Opin. 2024 Jan;40(1):69-75. doi: 10.1080/03007995.2023.2270894. Epub 2024 Jan 3.
Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open. 2022 Aug;7(4):100517. doi: 10.1016/j.esmoop.2022.100517. Epub 2022 Jul 1.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-003699-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CTR20171026
Identifier Type: REGISTRY
Identifier Source: secondary_id
BGB-A317-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.